PRN: Global Antipsychotic Drugs Market to Grow at a CAGR of 1.8% by 2021 - Driven by Rising Public Interest Toward Mental Health - Research and Markets

14/giu/2017 17:45:15 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 6 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Global Antipsychotic Drugs Market to Grow at a CAGR of 1.8% by 2021 - Driven by Rising Public Interest Toward Mental Health - Research and Markets

 
[14-June-2017]
 

DUBLIN, June 14, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Antipsychotic Drugs Market 2017-2021" report to their offering.

Logo

The global antipsychotic drugs market to grow at a CAGR of 1.84% during the period 2017-2021.

The report, Global Antipsychotic Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

One trend in the market is rising public interest toward mental health. The rising public interest for the management of depression by government bodies such as the CDC is an important trend being witnessed in the market. The CDC plays an important role in the integration of mental well-being with public health.

According to the report, one driver in the market is increasing expenditure on prescription drugs. The global antipsychotic drugs market has witnessed a large shift in the clinical and economic role of prescription drugs, owing to policy changes in the healthcare sector, availability of insurance coverage, the introduction of behavioral healthcare techniques, and marketing strategies adopted by pharmaceutical companies to promote their product.

Further, the report states that one challenge in the market is lack of standard diagnostic methods. Accurate diagnosis of a disease helps in prescribing appropriate treatment regimen and impact around 60% of physicians' clinical decision. Most of the mental disorders can be effectively managed if they are diagnosed at an early stage. However, the lack of suitable diagnostic procedures will lead to underdiagnosed population and treatment will become more complex if a disorder is diagnosed at an advanced stage.

Key vendors

  • AstraZeneca
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson

Other prominent vendors

  • Actavis Generics
  • Alkermes
  • Bristol-Myers Squibb

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Disease overview

PART 06: Key clinical trials

PART 07: Market landscape

PART 08: Market segmentation by disease type

PART 09: Market segmentation based on MoA

PART 10: Geographical segmentation

PART 11: Decision framework

PART 12: Drivers and challenges

PART 13: Market trends

PART 14: Vendor landscape

PART 15: Key vendor analysis

For more information about this report visit http://www.researchandmarkets.com/research/fpftc5/global

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl